Journal
Leukemia
Publication Date
9-1-2022
Volume
36
Issue
9
First Page
2261
Last Page
2268
Document Type
Open Access Publication
DOI
10.1038/s41375-022-01637-7
Rights and Permissions
Mesa, R., Harrison, C., Oh, S.T. et al. Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis. Leukemia 36, 2261–2268 (2022). https://doi.org/10.1038/s41375-022-01637-7 This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Recommended Citation
Mesa, Ruben; Oh, Stephen T; and et al, "Overall survival in the SIMPLIFY-1 and SIMPLIFY-2 phase 3 trials of momelotinib in patients with myelofibrosis." Leukemia. 36, 9. 2261 - 2268. (2022).
https://digitalcommons.wustl.edu/oa_4/194
Data Supplement
